Polymorphic repeat in AIB1 does not alter breast cancer risk
Open Access
- 1 October 2000
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research
- Vol. 2 (5) , 378-385
- https://doi.org/10.1186/bcr82
Abstract
We assessed the association between a glutamine repeat polymorphism in AIB1 and breast cancer risk in a case-control study (464 cases, 624 controls) nested within the Nurses' Health Study cohort. We observed no association between AIB1 genotype and breast cancer incidence, or specific tumor characteristics. These findings suggest that AIB1 repeat genotype does not influence postmenopausal breast cancer risk among Caucasian women in the general population.Keywords
This publication has 20 references indexed in Scilit:
- Androgen Receptor Exon 1 CAG Repeat Length and Breast Cancer in Women Before Age Forty YearsJNCI Journal of the National Cancer Institute, 1999
- A rare CYP19 (aromatase) variant may increase the risk of breast cancerPharmacogenetics, 1998
- AIB1, a Steroid Receptor Coactivator Amplified in Breast and Ovarian CancerScience, 1997
- The CAG repeat within the androgen receptor gene and its relationship to prostate cancerProceedings of the National Academy of Sciences, 1997
- A polymorphism in the CYP17 gene increases the risk of breast cancer.1997
- Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period.1995
- Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibilityHuman Genetics, 1994
- Human familial and sporadic breast cancer: analysis of the coding regions of the 17?-hydroxysteroid dehydrogenase 2 gene (EDH17B2) using a single-strand conformation polymorphism assayHuman Genetics, 1994
- The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation functionNucleic Acids Research, 1994
- Regression Analysis for Correlated DataAnnual Review of Public Health, 1993